---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-005124"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T20:16:42.846055+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aptose TUSCANY trial advances to 160 mg TUS dose; receives additional $1.1M loan from Hanmi

## Summary
- CSRC approved escalation to 160 mg TUS dose after no dose-limiting toxicities at 40, 80, and 120 mg cohorts.
- TUS+VEN+AZA triplet achieved CRs and MRD negativity in patients with adverse TP53 and FLT3-ITD mutations.
- Aptose received $1.1M advance from Hanmi under $8.5M loan, bringing total advances to $5.6M.
- Enrollment open for 160 mg cohort; all 120 mg patients remain on study.
- Trial anticipates enrolling 18-24 patients by late 2025.

## SEC filing metadata
- accession: 0001171843-25-005124
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000117184325005124/0001171843-25-005124-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000117184325005124/f8k_080625.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-005124
- JSON: https://secwatch.observer/filing/0001171843-25-005124.json
- Plain text: https://secwatch.observer/filing/0001171843-25-005124.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.